Cero Therapeutics Holdings, INC 8-K filings

CERO Therapeutics Holdings, Inc. has regained compliance with the Nasdaq minimum bid price requirement and has been moved to the Nasdaq Capital Market.

CERo Therapeutics announces a $5 million public offering of common stock and warrants priced at $1.96 per share.

CERO Therapeutics has received an extension from Nasdaq until April 22, 2025, to meet listing requirements, including a minimum bid price and stockholders' equity.

Cero Therapeutics Holdings issued common stock and warrants after a holder exercised preferred warrants, resulting in $500,000 in cash proceeds.

CERO Therapeutics Holdings reports a cash balance of approximately $5.463 million as of January 7, 2025, following proceeds from warrant exercises and equity line sales.

CERo Therapeutics Holdings, Inc. has implemented a 1-for-100 reverse stock split to increase its share price and regain compliance with Nasdaq listing requirements.

Cero Therapeutics Holdings reports the effectiveness of registration statements, warrant exercises, preferred stock conversions, and equity line issuances.

CERo Therapeutics has appointed Chris Ehrlich as its permanent CEO and plans to file an Investigational New Drug Application for CER-1236 in solid tumors in the first half of 2025.

CERo Therapeutics has received FDA clearance for its Investigational New Drug Application to begin Phase 1 clinical trials of its lead compound, CER-1236, for the treatment of acute myelogenous leukemia (AML).

CERO Therapeutics Holdings, Inc. has entered into a new purchase agreement for up to $20.6 million in common stock and received stockholder approval for a reverse stock split.

CERO Therapeutics Holdings, Inc. has received notice from Nasdaq that its securities will be delisted due to failure to meet the minimum Market Value of Listed Securities requirement, and the company has requested a hearing to appeal the decision.

CERO Therapeutics Holdings, Inc. has received a delisting notice from Nasdaq due to its stock price falling below $0.10 for ten consecutive trading days, despite a prior notice regarding the minimum $1.00 bid price requirement.

CERo Therapeutics has submitted a Complete Response Letter to the FDA regarding a clinical hold on CERO-1236 and now anticipates initiating human trials in early 2025.

CERO Therapeutics Holdings, Inc. reports a preliminary cash balance of $3.3 million as of September 30, 2024, and appoints Shami Patel to its Board of Directors.

CERo Therapeutics has appointed Andrew Kucharchuk as Chief Financial Officer and Kristen Pierce as Chief Development Officer, effective October 1, 2024, as part of a broader executive transition.

CERO Therapeutics Holdings, Inc. has completed a private placement, issuing Series C convertible preferred stock and warrants for approximately $1.25 million in gross proceeds.

CERO Therapeutics has cancelled its special stockholder meeting scheduled for September 26, 2024, and withdrawn the proposal for a reverse stock split.

CERo Therapeutics has obtained $1.25 million in financing, plans to address an FDA clinical hold on CER-1236, and has appointed a new interim CEO and Chairman.

CERO Therapeutics Holdings, Inc. announces the resignation of its Chief Financial Officer, Charles R. Carter, effective September 30, 2024, as he transitions to a new role at another public company.

CERO Therapeutics has announced a second postponement of its special stockholder meeting, now scheduled for September 26, 2024.

CERO Therapeutics has announced the postponement of its special stockholder meeting from September 12th to September 19th, with no changes to the record date.

The FDA has placed a clinical hold on CERO Therapeutics' Investigational New Drug Application for CER-1236 due to insufficient pharmacology and toxicology data.

CERO Therapeutics Holdings, Inc. has received notifications from Nasdaq regarding deficiencies in its stock price and market value, putting its listing at risk.

CERO Therapeutics has received a notification from Nasdaq regarding its failure to meet the minimum market value requirement for continued listing.

CERO Therapeutics stockholders approved several key proposals at a special meeting on April 30, 2024, including the ratification of their accounting firm and the issuance of common stock related to convertible securities and equity financings.

CERo Therapeutics Holdings, Inc. has completed its business combination with Phoenix Biotech Acquisition Corp., providing detailed financial statements and outlining future development plans.

CERO Therapeutics has entered into a purchase agreement with Arena Business Solutions for up to $25 million in common stock, providing flexible funding options.

CERO Therapeutics Holdings, Inc. has finalized its business combination with Phoenix Biotech Acquisition Corp., accompanied by a $9.98 million PIPE financing.

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. have completed their merger, establishing a new investor rights and lock-up agreement.

Phoenix Biotech Acquisition Corp. has amended its merger agreement with CERo Therapeutics, introducing additional earnout shares and modifying vesting conditions.